The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
APOL1 Variants Associate with Increased Risk of CKD among African Americans
Open accessAbstract
Although case-control studies suggest that African Americans with common coding variants in the APOL1 gene are 5-29 times more likely than those individuals without such variants to have focal segmental glomerulosclerosis, HIV-associated nephropathy, or ESRD, prospective studies have not yet evaluated the impact of these variants on CKD in a community-based sample of African Americans. Here, we studied whether the APOL1 G1 and G2 risk alleles associate with the development of CKD and progression to ESRD by analyzing data from 3067 African Americans in the Atherosclerosis Risk in Communities Study who did not have CKD at baseline. Carrying two risk alleles associated with a 1.49-fold increased risk of CKD (95% CI=1.02 to 2.17) and a 1.88-fold increased risk of ESRD (95% CI=1.20 to 2.93) compared with zero or one risk allele; associations persisted after adjusting for European ancestry. Among participants who developed CKD, those participants with two risk alleles were more likely to progress to ESRD than their counterparts with zero or one risk allele (HR=2.22, 95% CI=1.01 to 4.84). In conclusion, APOL1 risk variants are risk factors for the development of CKD and progression from CKD to ESRD among African Americans in the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Self-citationAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Self-citationPrevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Self-citation(1989) · PubMed · Cited by 3,139
Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans
Genovese, G., Friedman, D. J., Ross, M. D., Lecordier, L., Uzureau, P., Freedman, B. I., Bowden, D. W., Langefeld, C. D., Oleksyk, T. K., Uscinski Knob, A. L., et al. (2010) · Science · doi:10.1126/science.1193032 · Cited by 2,028
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy
Kopp, J. B., Nelson, G. W., Sampath, K., Johnson, R. C., Genovese, G., An, P., Friedman, D., Briggs, W., Dart, R., Korbet, S., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011040388 · Cited by 855
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis
Kopp, J. B., Smith, M. W., Nelson, G. W., Johnson, R. C., Freedman, B. I., Bowden, D. W., Oleksyk, T., McKenzie, L. M., Kajiyama, H., Ahuja, T. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.226 · Cited by 711
Tzur, S., Rosset, S., Shemer, R., Yudkovsky, G., Selig, S., Tarekegn, A., Bekele, E., Bradman, N., Wasser, W. G., Behar, D. M., et al. (2010) · Human Genetics · doi:10.1007/s00439-010-0861-0 · Cited by 653
MYH9 is associated with nondiabetic end-stage renal disease in African Americans
on behalf of the Family Investigation of Nephropathy and Diabetes (FIND) Research Group, Kao, W. H. L., Klag, M. J., Meoni, L. A., Reich, D., Berthier-Schaad, Y., Li, M., Coresh, J., Patterson, N., Tandon, A., et al. (2008) · Nature Genetics · doi:10.1038/ng.232 · Cited by 649
Self-citationEnd-stage renal disease in African-American and white men. 16-year MRFIT findings
Klag, M. J. (1997) · JAMA · doi:10.1001/jama.277.16.1293 · Cited by 612
Apolipoprotein L-I is the trypanosome lytic factor of human serum
Vanhamme, L., Paturiaux-Hanocq, F., Poelvoorde, P., Nolan, D. P., Lins, L., Van Den Abbeele, J., Pays, A., Tebabi, P., Van Xong, H., Jacquet, A., et al. (2003) · Nature · doi:10.1038/nature01461 · Cited by 500
Methods for High-Density Admixture Mapping of Disease Genes
Patterson, N., Hattangadi, N., Lane, B., Lohmueller, K. E., Hafler, D. A., Oksenberg, J. R., Hauser, S. L., Smith, M. W., O’Brien, S. J., Altshuler, D., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/420871 · Cited by 478
Microalbuminuria as an Early Marker for Cardiovascular Disease
de Zeeuw, D., Parving, H.-H., & Henning, R. H. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050517 · Cited by 399
Tarver-Carr, M. E., Powe, N. R., Eberhardt, M. S., LaVeist, T. A., Kington, R. S., Coresh, J., & Brancati, F. L. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000026493.18542.6a · Cited by 284
Self-citationChange in Estimated GFR Associates with Coronary Heart Disease and Mortality
Matsushita, K., Selvin, E., Bash, L. D., Franceschini, N., Astor, B. C., & Coresh, J. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009010025 · Cited by 276
Self-citationLipkowitz, M. S., Freedman, B. I., Langefeld, C. D., Comeau, M. E., Bowden, D. W., Linda Kao, W. H., Astor, B. C., Bottinger, E. P., Iyengar, S. K., Klotman, P. E., et al. (2013) · Kidney International · doi:10.1038/ki.2012.263 · Cited by 244
Self-citationAPOL1 Localization in Normal Kidney and Nondiabetic Kidney Disease
Madhavan, S. M., O'Toole, J. F., Konieczkowski, M., Ganesan, S., Bruggeman, L. A., & Sedor, J. R. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011010069 · Cited by 239
Apolipoprotein L, a New Human High Density Lipoprotein Apolipoprotein Expressed by the Pancreas
Duchateau, P. N., Pullinger, C. R., Orellana, R. E., Kunitake, S. T., Naya-Vigne, J., O'Connor, P. M., Malloy, M. J., & Kane, J. P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25576 · Cited by 227
Population-Based Risk Assessment of APOL1 on Renal Disease
Friedman, D. J., Kozlitina, J., Genovese, G., Jog, P., & Pollak, M. R. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011050519 · Cited by 226
Perneger, T. V. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430110121013 · Cited by 186
APOL1 Variants Increase Risk for FSGS and HIVAN but Not IgA Nephropathy
Papeta, N., Kiryluk, K., Patel, A. M., Sterken, R., Kacak, N., Snyder, H. J., Imus, P. H., Mhatre, A. N., Lawani, A. K., Julian, B. A., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011040434 · Cited by 127
Bash, L. D., Astor, B. C., & Coresh, J. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.09.006 · Cited by 100
Self-citationThe MYH9/APOL1 region and chronic kidney disease in European-Americans
O’Seaghdha, C. M., Parekh, R. S., Hwang, S., Li, M., Köttgen, A., Coresh, J., Yang, Q., Fox, C. S., & Kao, W. H. L. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr118 · Cited by 96
Self-citationFreedman, B. I., Langefeld, C. D., Turner, J., Núñez, M., High, K. P., Spainhour, M. H., Hicks, P. J., Bowden, D. W., Reeves‐Daniel, A., Murea, M., et al. (2012) · Kidney International · doi:10.1038/ki.2012.217 · Cited by 77
The population genetics of chronic kidney disease: insights from the MYH9–APOL1 locus
Rosset, S., Tzur, S., Behar, D. M., Wasser, W. G., & Skorecki, K. L. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.52 · Cited by 73
APOL1 and Progression of Nondiabetic Nephropathy
Palmer, N. D., & Freedman, B. I. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060589 · Cited by 28
Cited by
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Self-citationChronic Kidney Disease Diagnosis and Management: A Review
Chen, T. K., Knicely, D. H., & Grams, M. E. (2019) · JAMA · doi:10.1001/jama.2019.14745 · Cited by 1,811
Self-citationAPOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease
Parsa, A., Kao, W. H. L., Xie, D., Astor, B. C., Li, M., Hsu, C.-Y., Feldman, H. I., Parekh, R. S., Kusek, J. W., Greene, T. H., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310345 · Cited by 784
Self-citationThe ARIC (Atherosclerosis Risk In Communities) Study
Wright, J. D., Folsom, A. R., Coresh, J., Sharrett, A. R., Couper, D., Wagenknecht, L. E., Mosley, T. H., Ballantyne, C. M., Boerwinkle, E. A., Rosamond, W. D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.035 · Cited by 552
Self-citationTransgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice
Beckerman, P., Bi-Karchin, J., Park, A. S. D., Qiu, C., Dummer, P. D., Soomro, I., Boustany-Kari, C. M., Pullen, S. S., Miner, J. H., Hu, C.-A. A., et al. (2017) · Nature Medicine · doi:10.1038/nm.4287 · Cited by 344
Metadata
- Authors
- Foster, M. C., Coresh, J., Fornage, M., Astor, B. C., Grams, M., Franceschini, N., Boerwinkle, E., Parekh, R. S., & Kao, W. H. L.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2013-09
- Volume
- 24
- Issue
- 9
- Pages
- 1484-1491
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2138846140
- Cited by
- 267
- References
- 29
- FWCI
- 15.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.